乳腺癌患者生育力保存后的生殖结局:瑞典全国队列研究
该瑞典全国队列研究纳入1994至2017年确诊乳腺癌并接受生育力保存(FP)的425例女性,按年龄、诊断日历期和县匹配850例未接受FP的对照。FP组乳腺癌后活产率显著更高(aHR 2.3,95%CI 1.6-3.3),辅助生殖技术使用率更高(aHR 4.8,95%CI 2.2-10.7),全因死亡率更低(aHR 0.4,95%CI 0.3-0.7)。
要点
- FP组乳腺癌后活产率显著高于未FP组(aHR 2.3,95%CI 1.6-3.3)。
- FP组辅助生殖技术使用率更高(aHR 4.8,95%CI 2.2-10.7)。
- FP组全因死亡率更低(aHR 0.4,95%CI 0.3-0.7),未见生存负面影响。
核心结论
- 乳腺癌诊断时接受FP的女性乳腺癌后活产和辅助生殖技术治疗的可能性显著更高,且与全因生存无负相关。
研究设计与样本
- 瑞典全国队列研究,FP组为1994至2017年在区域FP项目接受FP的乳腺癌女性425例。
- 对照组为从区域乳腺癌登记中按年龄、诊断日历期和县匹配的850例无FP史的乳腺癌女性。
主要发现
- FP组97/425(22.8%)至少1次乳腺癌后活产,对照组74/850(8.7%)。
- FP组乳腺癌后活产的aHR为2.3(95%CI 1.6-3.3)。
- FP组乳腺癌后5年和10年活产累积发生率分别为19.4%和40.7%,对照组分别为8.6%和15.8%。
- FP组辅助生殖技术使用的aHR为4.8(95%CI 2.2-10.7)。
- FP组全因死亡aHR为0.4(95%CI 0.3-0.7),5年死亡累积发生率5.3%(95%CI 3.1%-9.0%) vs 11.1%(95%CI 8.7%-14.1%)。
临床怎么用
- 对育龄乳腺癌患者进行肿瘤治疗和生殖咨询时,可告知FP与更高的乳腺癌后活产及辅助生殖技术使用相关。
- FP与全因生存无负相关,支持在合适患者中开展生育力保存咨询。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The practice of fertility preservation (FP) in women with breast cancer (BC) is spreading, but long-term reproductive outcomes after FP are largely unknown. OBJECTIVE: To investigate the long-term reproductive outcomes in women who did or did not undergo FP at the time of BC diagnosis. DESIGN, SETTING, AND PARTICIPANTS: A Swedish nationwide cohort study was conducted to investigate the long-term reproductive outcomes of women with BC receiving FP at 1 of the regional FP programs from 1994 to 2017 (n = 425). Population comparators with BC but without history of FP (n = 850) were sampled from regional BC registers, matched on age, calendar period of diagnosis, and county. Data on live births, assisted reproductive technology (ART) use, and mortality were retrieved from population-based registers. Data analysis was performed from January to September 2020. EXPOSURES: History of having received FP compared with no history of FP (unexposed). MAIN OUTCOMES AND MEASURES: The primary outcome was hazard ratios (HRs) of live births and ART treatments following BC in women with vs without FP and the cumulative incidence of these events in the presence of the competing risk of death. RESULTS: Women who had undergone FP (n = 425) had lower parity (302 [71.1%] were nulliparous compared with 171 [20.1%] in the unexposed group), were younger (mean [SD] age, 32.1 [4.0] vs 33.3 [3.6] years), more often had estrogen receptor-positive tumors (289 [68.0%] vs 515 [60.6%]), and were more often scheduled for chemotherapy (399 [93.9%] vs 745 [87.7%]). Of 425 women exposed to FP, 97 (22.8%) had at least 1 post-BC live birth (mean follow-up, 4.6 years), compared with 74 of 850 women (8.7%) unexposed to FP (mean follow-up, 4.8 years). Overall, live birth rates after BC were significantly higher among women with FP (adjusted hazard ratio [aHR], 2.3; 95% CI, 1.6-3.3). The 5-year and 10-year cumulative incidence of post-BC live births was 19.4% and 40.7% among FP-exposed women vs 8.6% and 15.8% among comparators, respectively. Rates of ART use were also higher in the FP group (aHR, 4.8; 95% CI, 2.2-10.7). The all-cause mortality rate was lower in women exposed to FP (aHR, 0.4; 95% CI, 0.3-0.7), with 5-year cumulative incidence of death of 5.3% (95% CI, 3.1%-9.0%) vs 11.1% (95% CI, 8.7%-14.1%) for women with vs without FP. CONCLUSIONS AND RELEVANCE: In this cohort study of Swedish women after a BC diagnosis, successful pregnancy after BC was possible both in women with and without FP at the time of diagnosis, but a significantly higher likelihood of post-BC live births and ART treatments was observed in women who underwent FP, without any negative association with all-cause survival. This information is valuable for health care clinicians responsible for oncologic treatment and reproductive counseling of women diagnosed with breast cancer at reproductive age.
引用
- Marklund A, Lundberg FE, Eloranta S, et al. Reproductive Outcomes After Breast Cancer in Women With vs Without Fertility Preservation. JAMA Oncol. 2021. PMID: 33211089. doi:10.1001/jamaoncol.2020.5957
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。